News - Muscle relaxant
XenoPort, Inc. (Nasdaq:XNPT) announced plans to initiate an exploratory Phase 2 clinical trial of XP19986 in patients with acute back spasms, which is a debilitating condition affecting approximately two-thirds of patients experiencing lower back pain.
LA JOLLA, Calif., Oct. 17 /PRNewswire/ -- Tezampanel, a novel small molecule currently in clinical development by TorreyPines Therapeutics, Inc.
By The Associated Press WASHINGTON - A Pfizer Inc. drug won expanded federal approval Thursday as the first treatment for fibromyalgia, a mysterious syndrome marked by muscle pain and fatigue.
WASHINGTON - A Pfizer Inc. drug won expanded federal approval Thursday as the first treatment for fibromyalgia, a mysterious syndrome marked by muscle pain and fatigue.